Getz Pharma issues this statement in response to the recent dissemination of false information about its product Risek IV 40 mg injection on electronic and social media. These malicious attempts aim to undermine the brand reputation of our product.
On February 12, 2024, the Federal Inspector of Drugs-IV, while conducting market surveillance in Moro, Sindh, identified counterfeit Risek 40mg IV injections at the premises of M/s Qalanari Medicos on Hospital Road, Moro, Nowsheroferoz. Samples were sent for testing, including confirmation by Getz Pharma. We confirmed the sample as counterfeit, not manufactured by us, and provided a comparative analysis report to authorities, urging action.
Getz Pharma condemns the misreporting by the electronic media of the Alert issued by Drug Regulatory Authority of Pakistan (DRAP) as if our manufactured product was deemed spurious or counterfeit, requiring recall. These reports completely disregard our stance of disowning of the counterfeit sample provided in the same Alert. Nevertheless, we reserve the right to take legal action against false reporting.
Getz Pharma manufactures safe and efficacious medicines in its WHO, PIC/s, and EAEU prequalified manufacturing facility. Stakeholders, including doctors, patients, chemists, and customers, should beware of misinformation and rely on credible sources.—PR
